19.35 USD
+0.44 (+2.33%)
19.3799 USD
+0.03 (+0.15%)
Overall SRPT gets a fundamental rating of 3 out of 10. We evaluated SRPT against 533 industry peers in the Biotechnology industry. SRPT may be in some trouble as it scores bad on both profitability and health. SRPT is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year SRPT has reported negative net income.
SRPT had a negative operating cash flow in the past year.
SRPT had negative earnings in 4 of the past 5 years.
In the past 5 years SRPT reported 4 times negative operating cash flow.
1.2 Ratios
SRPT has a better Return On Assets (-7.77%) than 86.12% of its industry peers.
SRPT's Return On Equity of -20.57% is amongst the best of the industry. SRPT outperforms 83.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROIC | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
With an excellent Gross Margin value of 76.25%, SRPT belongs to the best of the industry, outperforming 83.68% of the companies in the same industry.
SRPT's Gross Margin has been stable in the last couple of years.
SRPT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
2. Health
2.1 Basic Checks
SRPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, SRPT has more shares outstanding
Compared to 5 years ago, SRPT has more shares outstanding
The debt/assets ratio for SRPT has been reduced compared to a year ago.
2.2 Solvency
SRPT has an Altman-Z score of -0.09. This is a bad value and indicates that SRPT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.09, SRPT is in the better half of the industry, outperforming 60.98% of the companies in the same industry.
SRPT has a Debt/Equity ratio of 0.78. This is a neutral value indicating SRPT is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.78, SRPT is not doing good in the industry: 73.73% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.09 |
ROIC/WACCN/A
WACC7.3%
2.3 Liquidity
A Current Ratio of 2.95 indicates that SRPT has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.95, SRPT is doing worse than 63.79% of the companies in the same industry.
A Quick Ratio of 1.79 indicates that SRPT should not have too much problems paying its short term obligations.
The Quick ratio of SRPT (1.79) is worse than 77.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 |
3. Growth
3.1 Past
SRPT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -197.60%.
The Revenue has grown by 47.15% in the past year. This is a very strong growth!
SRPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 37.94% yearly.
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
3.2 Future
The Earnings Per Share is expected to grow by 7.24% on average over the next years.
The Revenue is expected to decrease by -5.07% on average over the next years.
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
SRPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 7.98, the valuation of SRPT can be described as very cheap.
Based on the Price/Forward Earnings ratio, SRPT is valued cheaply inside the industry as 98.69% of the companies are valued more expensively.
When comparing the Price/Forward Earnings ratio of SRPT to the average of the S&P500 Index (35.79), we can say SRPT is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.98 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y3.1%
EPS Next 3Y2.13%
5. Dividend
5.1 Amount
No dividends for SRPT!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
19.35
+0.44 (+2.33%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners81.76%
Inst Owner Change1.91%
Ins Owners4.63%
Ins Owner Change10.75%
Market Cap2.03B
Revenue(TTM)2.41B
Net Income(TTM)-271.51M
Analysts68
Price Target32.03 (65.53%)
Short Float %17.35%
Short Ratio2.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)122.82%
Min EPS beat(2)98.8%
Max EPS beat(2)146.84%
EPS beat(4)2
Avg EPS beat(4)-38.28%
Min EPS beat(4)-376.26%
Max EPS beat(4)146.84%
EPS beat(8)6
Avg EPS beat(8)621.83%
EPS beat(12)9
Avg EPS beat(12)401.46%
EPS beat(16)10
Avg EPS beat(16)286.26%
Revenue beat(2)2
Avg Revenue beat(2)14.32%
Min Revenue beat(2)13.04%
Max Revenue beat(2)15.59%
Revenue beat(4)4
Avg Revenue beat(4)9.59%
Min Revenue beat(4)2.86%
Max Revenue beat(4)15.59%
Revenue beat(8)7
Avg Revenue beat(8)6.15%
Revenue beat(12)10
Avg Revenue beat(12)5.55%
Revenue beat(16)12
Avg Revenue beat(16)4.13%
PT rev (1m)-2.73%
PT rev (3m)-4.63%
EPS NQ rev (1m)-13.72%
EPS NQ rev (3m)-76.24%
EPS NY rev (1m)1.27%
EPS NY rev (3m)7.8%
Revenue NQ rev (1m)8.02%
Revenue NQ rev (3m)8.15%
Revenue NY rev (1m)0.48%
Revenue NY rev (3m)0.72%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 7.98 | ||
| P/S | 0.84 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.53 | ||
| P/tB | 1.57 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.22
EYN/A
EPS(NY)2.42
Fwd EY12.52%
FCF(TTM)-3.71
FCFYN/A
OCF(TTM)-2.34
OCFYN/A
SpS23.06
BVpS12.61
TBVpS12.33
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 76.25% | ||
| FCFM | N/A |
ROA(3y)-10.99%
ROA(5y)-12.97%
ROE(3y)-76.57%
ROE(5y)-69.51%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-0.45%
F-Score3
Asset Turnover0.69
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.78 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 290.01% | ||
| Cap/Sales | 5.97% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.95 | ||
| Quick Ratio | 1.79 | ||
| Altman-Z | -0.09 |
F-Score3
WACC7.3%
ROIC/WACCN/A
Cap/Depr(3y)221.92%
Cap/Depr(5y)219.29%
Cap/Sales(3y)6.11%
Cap/Sales(5y)8.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-197.6%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-102.94%
EPS Next Y-292.84%
EPS Next 2Y3.1%
EPS Next 3Y2.13%
EPS Next 5Y7.24%
Revenue 1Y (TTM)47.15%
Revenue growth 3Y39.42%
Revenue growth 5Y37.94%
Sales Q2Q%-14.52%
Revenue Next Year9.8%
Revenue Next 2Y-7.51%
Revenue Next 3Y-7.56%
Revenue Next 5Y-5.07%
EBIT growth 1Y-206.15%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-229.84%
EBIT Next 3Y13.2%
EBIT Next 5Y10.53%
FCF growth 1Y36.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y54.58%
OCF growth 3YN/A
OCF growth 5YN/A
SAREPTA THERAPEUTICS INC / SRPT FAQ
What is the ChartMill fundamental rating of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a fundamental rating of 3 / 10 to SRPT.
What is the valuation status of SAREPTA THERAPEUTICS INC (SRPT) stock?
ChartMill assigns a valuation rating of 2 / 10 to SAREPTA THERAPEUTICS INC (SRPT). This can be considered as Overvalued.
How profitable is SAREPTA THERAPEUTICS INC (SRPT) stock?
SAREPTA THERAPEUTICS INC (SRPT) has a profitability rating of 3 / 10.
What is the earnings growth outlook for SAREPTA THERAPEUTICS INC?
The Earnings per Share (EPS) of SAREPTA THERAPEUTICS INC (SRPT) is expected to decline by -292.84% in the next year.